Sildenafil for pulmonary hypertension in neonates

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Pharmacology

Background:

• Persistent pulmonary hypertension in neonates (PPHN) is a critical condition with high mortality.
• Current treatments like inhaled nitric oxide (iNO) are not universally accessible or effective for all patients.
• Sildenafil, a phosphodiesterase inhibitor, is being investigated as an alternative therapy for PPHN.

Purpose of the Study:

• To evaluate the efficacy and safety of sildenafil in treating neonates with PPHN.
• To assess sildenafil's impact on oxygenation and mortality in PPHN patients.

Main Methods:

• A systematic review of randomized or quasi-randomized controlled trials was conducted.
• Searches included major databases (MEDLINE, EMBASE, CINAHL) and trial registries up to March 2007.
• Two small trials involving 37 neonates in resource-limited settings were included.

Main Results:

• Sildenafil significantly improved oxygenation (reduced oxygenation index) in neonates with PPHN.
• One study indicated a potential mortality benefit with sildenafil, though this requires larger study validation.
• No significant adverse side effects were reported in the included trials.

Conclusions:

• The efficacy and safety of sildenafil for PPHN are not yet definitively established.
• Current use of sildenafil for PPHN should be limited to clinical trials.
• Larger, adequately powered randomized controlled trials are necessary to confirm sildenafil's role in PPHN management.